KTTA

Rating neutralAI MemoPost-earnings T+3

Pasithea Therapeutics

As of 2026-08-17/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 liquidity checkpoint • 2026-08-14

Base target: $1 / p=50% prob

Biggest risk

Clinical efficacy remains preliminary and uncontrolled, final progression-free-survival data are not yet known, and the Q2 filing shows ongoing losses, $9.5 million of six-month operating cash burn, and dependence on future equity or debt funding [#SEC-10Q-2026-08-14]. No post-print analyst estimate, rating, or price-target revision was available.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The June 30 company update reported 34 advanced-cancer patients, no dose-limiting toxicities, no treatment-related discontinuations, and durable stable disease in several heavily pretreated patients; the ESMO presentation is the clearest potential rerating trigger [#IR-2026-06-30].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-17

Base target

p=50%

Bull target

p=15%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

NF1 interim clinical data
The June 30 company update reported 34 advanced-cancer patients, no dose-limiting toxicities, no treatment-related discontinuations, and durable stable disease in several heavily pretreated patients; the ESMO presentation is the clearest potential rerating trigger [#IR-2026-06-30].
At an anchor price of $0.4805 and approximately $16.1 million market capitalization, valuation is dominated by clinical probability and dilution risk.

BearKey bullets

Coverage is low and no reliable post-earnings consensus surprise, analyst revision, or attributed market-reaction data was available.
Early clinical signals may not translate into confirmed efficacy or regulatory approval; the company explicitly notes that future results may be negative or ambiguous [#IR-2026-06-30].
Higher-dose escalation and the ESMO data release could disappoint, especially because current findings remain interim and the final PFS outcome is unknown [#IR-2026-06-30] [#IR-2026-07-21].

WatchKey bullets

Q2 2026 liquidity checkpoint

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $1 (p=50%)

Target spread vs base: +120% / -60%

Scenario probabilities

Bull Target: $1 (p=15%)Base Target: $1 (p=50%)Bear Target: $0 (p=35%)

Commentary

The Q2 2026 10-Q was filed August 14, but no separate August 12 earnings release, transcript, consensus surprise, or analyst revision was located. The post-print fundamental signal is mixed: cash supports at least 12 months of operations, while burn and stated future funding needs remain material [#SEC-10Q-2026-08-14]. Recent company headlines are constructive, but price reaction cannot be confidently attributed to the filing and low coverage limits confidence.

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

NF1 interim clinical data

Scenarios

Bull Target (Scenario probability)

$1 / p=15% prob

Base Target (Scenario probability)

$1 / p=50% prob

Bear Target (Scenario probability)

$0 / p=35% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-14
Q2 2026 liquidity checkpoint
The August 14 10-Q reported $45.7 million of cash and equivalents as of June 30, 2026 and no substantial doubt about funding the next 12 months, but also disclosed $9.5 million of six-month operating cash burn and a need for significant additional capital [#SEC-10Q-2026-08-14].
Prob 100.00% • Move 2.00% • Priced-in 75.00%
EVENT2026-10-23
ESMO PAS-004 data presentation
Pasithea announced that PAS-004 Phase 1 dose-escalation data will be presented on October 23, 2026, with a follow-up release of detailed results planned [#IR-2026-07-21].
Prob 85.00% • Move 30.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

NF1 interim clinical data
2026-12-31
The prior company update identified a Q4 2026 interim NF1 data target while the Phase 1/1b study progresses. This remains a high-volatility, early-stage readout rather than a confirmed efficacy inflection [#IR-2026-06-16].
Prob 60% • Move 45% • Priced-in 30%

Risks

Coverage is low and no reliable post-earnings consensus surprise, analyst revision, or attributed market-reaction data was available.
Early clinical signals may not translate into confirmed efficacy or regulatory approval; the company explicitly notes that future results may be negative or ambiguous [#IR-2026-06-30].
Higher-dose escalation and the ESMO data release could disappoint, especially because current findings remain interim and the final PFS outcome is unknown [#IR-2026-06-30] [#IR-2026-07-21].
The Q2 filing shows 33.4 million shares outstanding versus 23.1 million at year-end 2025, alongside substantial warrants and options, increasing dilution sensitivity [#SEC-10Q-2026-08-14].
The company expects significant additional capital and has no committed credit facility, creating financing and dilution risk [#SEC-10Q-2026-08-14].

Peers

Symbol	Summary
HIND	Loose same-sector microcap comparator; useful mainly for financing and clinical-event volatility context.
LEXX	Same-sector microcap biotech comparator with limited direct PAS-004 indication overlap.
NRSN	Small-cap biotech comparator relevant to development-stage and capital-markets risk, not direct valuation.
PTN	Same-sector microcap comparator with broad clinical-stage risk similarities but limited program read-through.
TPST	Biotech event-volatility comparator; useful for clinical execution context rather than direct operating comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

HIND

Loose same-sector microcap comparator; useful mainly for financing and clinical-event volatility context.

LEXX

Same-sector microcap biotech comparator with limited direct PAS-004 indication overlap.

NRSN

Small-cap biotech comparator relevant to development-stage and capital-markets risk, not direct valuation.

PTN

Same-sector microcap comparator with broad clinical-stage risk similarities but limited program read-through.

TPST

Biotech event-volatility comparator; useful for clinical execution context rather than direct operating comparison.